Combining Liver-directed Therapy With Systemic Therapy When Treating Patients With Gastrointestinal NETs

Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the results of combining liver-directed therapy with systemic therapy when treating patients with gastrointestinal neuroendocrine tumors.

Pharmacy Times interviewed Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors (NETs) Medical Virtual Symposium discussing sequencing and combination of liver-directed therapy (LDT) with systemic therapies.

During the interview, Gabriel discussed the results of combining LDT with systemic therapy when treating patients with gastrointestinal NETs.

Related Content:

OncologySpecialty PharmacyHospital
Understanding of Mutations Influences Treatment for Patients With Waldenstrom Macroglobulinemia
Clinical Overview: Empagliflozin for Type 2 Diabetes Patients With Cardiovascular Disease or Heart Failure, Reduced Ejection Fraction
Monjuvi Demonstrates Long-Term Efficacy for Individuals With R/R DLBCL